Septerna (SEPN) Return on Capital Employed (2024 - 2026)

Septerna's (SEPN) quarterly Return on Capital Employed came in at 11.03% in Q1 2026, up 996.0% year-on-year from 1.01% in Q1 2025, and up 16.89% quarter-over-quarter from 13.27% in Q4 2025.

Septerna (SEPN) Return on Capital Employed (2024 - 2026) Analysis & Trends

Septerna's Return on Capital Employed history runs 3 years deep, the most recent figure standing at 11.03% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 996.0% year-over-year to 11.03% in Q1 2026; TTM through Mar 2026 was 11.03%, a 996.0% increase from a year earlier, with the FY2025 full-year figure at 15.54%, up 1323.0% from the prior year.
  • Return on Capital Employed grew to 11.03% in Q1 2026 per SEPN's latest filing, from 13.27% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 11.03% in Q1 2026 and bottomed at 26.71% in Q4 2024.
  • The 3-year median for Return on Capital Employed is 19.33% (2025), against an average of 19.11%.
  • Across the five-year window, Return on Capital Employed soared 1344 bps in 2025 and soared 996 bps in 2026, its largest moves.
  • Year by year, Return on Capital Employed stood at 26.71% in 2024, then surged by 50 bps to 13.27% in 2025, then climbed by 17 bps to 11.03% in 2026.
  • Per Business Quant, the three latest SEPN Return on Capital Employed figures stand at 11.03% (Q1 2026), 13.27% (Q4 2025), and 17.67% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -31.80%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 10.46%
4 NuCana 279.75 Bn 279.75 Bn - -68.47%
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 21.10%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 10.19%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -68.84%
10 Septerna 1.50 Bn 1.50 Bn - -11.03%

Historic Data

Download Data
DateValue
Mar 31, 2026 -11.03%
Dec 31, 2025 -13.27%
Sep 30, 2025 -17.67%
Jun 30, 2025 -24.95%
Mar 31, 2025 -20.99%
Dec 31, 2024 -26.71%